NICE turns down Shire’s Revestive for bowel condition
The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funding for Shire’s Revestive as a treatment for short bowel syndrome (SBS).
Read More
Tag: glucagon-like peptide-2
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
